Abbisko Cayman (HKG:2256) said unit Abbisko Therapeutics received clearance for the IND application for ABSK061 from China's National Medical Products Administration for the treatment of children with achondroplasia, a Wednesday filing with the Hong Kong bourse said.
The firm will conduct a phase I/II clinical study of the drug for the relevant treatment.